previou
studi
show
recombin
modifi
vaccinia
ankara
mva
viru
express
ahsv
serotyp
induc
viru
neutralis
antibodi
hors
protect
interferon
alpha
receptor
gene
knockout
mice
ifnar
challeng
follow
experi
indic
passiv
transfer
antiserum
immun
donor
recipi
mice
h
challeng
confer
complet
clinic
protect
significantli
reduc
viraemia
studi
extend
determin
protect
effect
vaccineinduc
antiserum
administ
h
h
challeng
addit
passiv
transfer
splenocyt
undertaken
assess
confer
degre
immun
immunolog
recipi
mice
thu
antisera
splenocyt
collect
group
mice
vaccin
wild
type
mva
mvawt
passiv
immunis
recipi
mice
latter
subsequ
challeng
togeth
appropri
vaccin
unvaccin
control
anim
protect
assess
compar
clinic
sign
lethal
viraemia
treat
control
group
antiserum
recipi
show
high
protect
diseas
surviv
rate
even
mice
immunis
h
challeng
statist
signific
reduct
viraemia
comparison
control
group
mous
group
receiv
splenocyt
vaccin
show
surviv
rate
small
reduct
viraemia
compar
mice
receiv
splenocyt
mvawt
vaccin
result
confirm
primarili
humor
natur
protect
immun
confer
vaccin
show
potenti
administ
specif
antiserum
emerg
treatment
ahsv
african
hors
sick
ah
arthropodborn
viral
diseas
solip
transmit
haematophag
insect
genu
culicoid
hors
sever
affect
speci
mortal
rate
ahsv
outbreak
immunolog
popul
may
exceed
mellor
hamblin
differ
isol
strain
serotyp
african
hors
sick
viru
ahsv
classifi
within
speci
african
hors
sick
viru
genu
orbiviru
famili
reovirida
ahsv
close
relat
bluetongu
viru
caus
bluetongu
diseas
rumin
orbivirus
characteris
genom
compos
ten
linear
segment
dsrna
one
copi
ten
segment
packag
within
viru
particl
spheric
nonenvelop
capsid
ahsv
approxim
nm
diamet
compos
three
concentr
protein
layer
roy
et
al
outercapsid
layer
form
two
major
structur
protein
encod
genomeseg
respect
primarili
involv
cell
attach
cell
entri
variabl
antigen
ahsv
respons
serotyp
definit
burrag
et
al
ahsv
infect
hors
often
result
sever
clinic
diseas
death
although
anim
surviv
exhibit
solid
lifelong
serotypespecif
immun
humor
natur
ah
immun
associ
viru
neutralis
antibodi
vnab
hors
mice
use
colostrum
blackburn
swanepoel
burrag
et
al
crafford
et
al
main
target
vnab
ahsv
burrag
et
al
sever
studi
map
neutralis
epitop
amino
termin
half
protein
bentley
et
al
martineztorrecuadrada
casal
martineztorrecuadrada
et
al
although
less
import
respect
appear
directli
involv
format
viru
neutralis
epitop
indirectli
involv
influenc
conform
martineztorrecuadrada
casal
martineztorrecuadrada
et
al
unsurprisingli
experiment
vaccin
base
outercapsid
protein
andor
success
castilloolivar
et
al
chiam
et
al
romito
et
al
roy
sutton
scanlen
et
al
stonemarschat
et
al
recent
cellmedi
immun
respons
detect
hors
follow
inocul
live
attenu
ahsv
vaccin
pretoriu
et
al
recombin
canarypox
viru
express
ahsv
el
garch
et
al
recent
cellmedi
immun
respons
also
observ
interferon
alpha
receptor
gene
knockout
mice
ifnar
vaccin
singl
mva
recombin
virus
express
ahsv
de
la
poza
et
al
sinc
cellular
immun
associ
protect
btv
gener
assum
appli
ahsv
show
mva
express
ahsv
protect
ahsv
infect
mice
castilloolivar
et
al
hors
alberca
et
al
mechan
immun
underli
protect
effect
vaccin
investig
passiv
transfer
ahsv
neutralis
antiserum
vaccin
mice
immunolog
recipi
shown
highli
protect
lethal
ahsv
challeng
paper
followup
studi
investig
rel
contribut
humor
cellmedi
immun
protect
confer
vaccin
use
passiv
immunis
recipi
ifnar
mice
splenocyt
antiserum
vaccin
mice
describ
chicken
embryo
fibroblast
atcc
cat
vero
cell
atcc
grown
dulbecco
modifi
eagl
medium
dmem
supplement
mm
glutamin
penicillin
unitsml
streptomycin
lgml
foetal
calf
serum
fc
grown
vero
cell
mva
virus
grown
cell
viru
stock
gener
infect
confluent
cell
use
multipl
infect
moi
h
postinfect
total
cytopath
effect
cpe
visibl
cell
supernat
harvest
centrifug
viru
releas
cell
three
freez
thaw
cycl
titrat
plaqu
assay
viru
use
studi
previous
describ
chiam
et
al
ifn
ab
roo
ifnar
mice
background
purchas
b
k
univers
ltd
uk
eightweek
old
mice
use
throughout
mice
maintain
pathogenfre
condit
allow
acclimatis
biosafeti
level
anim
facil
centro
de
investigacion
en
sanidad
anim
inia
madrid
iniacisa
week
use
experi
live
anim
perform
guidelin
european
commun
approv
ethic
review
committe
iniacisa
ceea
murin
immunis
mvawt
prepar
donor
antisera
splenocyt
group
mice
vaccin
pfumous
either
group
group
mvawt
group
use
donor
serum
splenocyt
shown
tabl
third
dose
given
day
mice
group
mous
mice
group
group
euthanis
day
mice
group
euthan
day
splenocyt
blood
sampl
collect
termin
subsequ
use
passiv
immunis
blood
use
prepar
donor
antisera
pool
spleen
cell
obtain
mice
group
group
mvawt
transfer
via
intraven
inject
cellsmous
immunolog
recipi
group
tabl
transfer
perform
h
infect
pfumous
donor
antisera
prepar
pool
individu
serum
sampl
group
respect
tabl
donor
antisera
inactiv
min
use
intraperiton
inject
group
recipi
ifnar
mice
group
receiv
undilut
antiserum
administ
h
challeng
b
group
receiv
dilut
antiserum
administ
h
challeng
c
group
receiv
h
challeng
group
receiv
antiserum
challeng
passiv
immunis
mice
challeng
pfu
administ
subcutan
mvawt
group
group
vaccin
control
mice
infect
time
recipi
clinic
sign
viraemia
evalu
anim
follow
challeng
follow
challeng
anim
monitor
twice
daili
regularli
least
three
time
per
day
onset
sign
morbid
includ
chang
behaviour
activ
tabl
vaccin
prepar
splenocyt
antiserum
donor
day
day
day
day
mice
pfumous
pfumous
pfumous
collect
serum
mice
pfumous
pfumous
collect
serum
spleen
mice
mvawt
pfumous
mvawt
pfumous
collect
serum
spleen
chang
water
food
intak
alter
hair
coat
appear
bodi
weight
loss
presenc
ocular
sign
conjunct
ocular
discharg
swell
chang
hydrat
presenc
neurolog
sign
ie
paresi
paralysi
ataxia
human
endpoint
euthanasia
includ
persist
hunch
sever
conjunct
sign
dehydr
loss
bodi
weight
presenc
neurolog
sign
condit
prevent
food
water
intak
anim
display
clinic
sign
human
euthanis
cervic
disloc
follow
anaesthesia
isofluran
clinic
score
system
use
tabl
wherebi
anim
receiv
clinic
score
valu
per
day
valu
use
analysi
individu
mean
clinic
score
studi
period
sum
daili
score
animalnumb
day
determin
vnab
titr
serum
sampl
carri
describ
previous
briefli
twofold
serial
dilut
serum
sampl
incub
h
overnight
follow
day
vero
cell
ad
well
incub
day
co
endpoint
assay
highest
dilut
prevent
ahsv
cytopath
effect
well
antibodi
titr
calcul
accord
karber
antibodi
level
antibodi
serum
determin
previous
describ
calvopinilla
et
al
whole
blood
anim
collect
edta
regular
interv
challeng
volum
blood
wash
pb
mix
water
lyse
cell
pb
ad
sampl
infecti
viru
measur
standard
plaqu
assay
vero
cell
spleen
homogenis
filter
lm
cell
strainer
erythrocyt
lyse
nh
cl
remain
cell
resuspend
rpmi
media
ahsvspecif
ifnc
produc
cell
measur
elispot
assay
describ
previous
calvopinilla
et
al
splenocyt
stimul
h
either
cell
extract
inactiv
min
exposur
ultraviolet
light
jcm
affin
purifi
express
recombin
baculoviru
chiam
et
al
pha
phytohemagglutinin
lgml
stimul
control
cell
use
posit
control
uninfect
cell
extract
stimul
cell
use
neg
control
spot
count
antigenspecif
cell
calcul
spot
count
differ
cell
nonstimul
cell
unless
otherwis
state
method
use
splenocyt
serum
transfer
experi
viru
neutralis
titr
vnt
donor
mice
titr
mva
mvawt
vaccin
mice
splenocyt
transfer
mice
vaccin
twice
three
time
serum
transfer
compar
use
wilcoxon
ranksum
test
elispot
data
donor
mice
number
cell
excret
ifnc
compar
use
kruskalw
test
mice
group
accord
vaccin
statu
mvawt
stimulu
ahsv
ie
four
group
total
differ
group
explor
use
post
hoc
wilcoxon
ranksum
test
clinic
score
recipi
mice
clinic
score
differ
group
mice
compar
use
wilcoxon
ranksum
test
splenocyt
transfer
kruskalw
test
serum
transfer
latter
case
differ
group
explor
use
post
hoc
wilcoxon
ranksum
test
viraemia
recipi
mice
differ
viraemia
amongst
group
mice
assess
use
linear
mix
model
log
pfu
respons
variabl
day
post
infect
factor
group
fix
effect
mous
random
effect
model
select
proceed
stepwis
delet
nonsignific
term
judg
akaik
inform
criterion
start
model
includ
day
post
infect
group
main
effect
surviv
recipi
mice
surviv
differ
group
mice
compar
use
logrank
test
vnt
recipi
mice
titr
experi
end
point
either
death
day
post
infect
analys
use
oneway
analysi
varianc
follow
post
hoc
tukey
test
identifi
differ
group
signific
level
p
use
analys
method
implement
r
version
r
core
team
recent
demonstr
immunolog
mice
protect
challeng
virul
strain
administ
serum
mice
previous
vaccin
suggest
protect
afford
vaccin
mediat
mainli
antibodi
calvopinilla
et
al
howev
shown
studi
vaccin
also
induc
tcell
respons
studi
extend
determin
whether
adopt
transfer
splenocyt
vaccin
could
protect
infect
b
whether
protect
passiv
immunis
antibodi
vaccin
mice
could
observ
administ
h
h
challeng
serum
splenocyt
obtain
mice
vaccin
mvawt
indic
section
consist
previou
find
castilloolivar
et
al
mice
show
sign
infect
follow
vaccin
develop
vnab
respons
titr
day
follow
two
vaccin
rang
averag
subsequ
boost
day
averag
titr
antibodi
vaccin
also
detect
elisa
day
mean
od
valu
sd
mean
od
valu
sd
antisera
collect
day
use
passiv
immunis
adopt
transfer
splenocyt
carri
use
spleen
harvest
mvawt
vaccin
collect
day
result
ifnc
elispot
assay
fig
confirm
splenocyt
vaccin
donor
mice
function
secret
ifnc
frequenc
respond
cell
significantli
higher
mvawt
vaccin
mice
regardless
whether
stimul
ahsv
sampl
mice
could
use
assay
donor
splenocyt
confirm
viabl
function
ifnc
elispot
assay
transfer
group
recipi
mice
subsequ
challeng
assess
protect
capac
cellmedi
immun
mice
group
receiv
splenocyt
mvawt
vaccin
three
group
receiv
splenocyt
succumb
infect
tabl
ahsv
detect
blood
mice
group
fig
surviv
rate
viraemia
level
group
differ
significantli
p
group
howev
reduct
clinic
score
valu
group
rel
group
statist
signific
p
altogeth
data
indic
cell
mediat
immun
play
critic
role
high
level
protect
afford
homolog
serotyp
vaccin
see
tabl
studi
influenc
time
administr
dose
antiserum
protect
ahsv
evalu
thu
two
group
mice
passiv
immunis
indic
section
subsequ
infect
togeth
two
vaccin
group
expect
mice
vaccin
mvawt
group
develop
clinic
sign
typic
ah
ifnar
mous
model
tabl
start
day
postinfect
reach
human
endpoint
day
postchalleng
mice
group
euthanis
contrast
mice
group
surviv
challeng
develop
mild
clinic
sign
surviv
significantli
p
lower
mice
group
compar
group
clinic
score
also
significantli
higher
p
group
compar
group
group
compar
group
differ
viraemia
level
also
signific
p
highest
group
rel
group
also
evid
group
rel
group
fig
thu
level
protect
serum
transfer
experi
rank
follow
order
group
group
group
group
group
group
data
collect
indic
transfer
antiserum
protect
given
time
window
plu
minu
h
around
time
challeng
protect
defin
complet
prevent
lethal
ahsv
infect
signific
reduct
clinic
sign
signific
reduct
viraemia
everi
sampl
point
protect
maximum
dose
increas
group
llmous
administr
perform
prior
viru
challeng
group
serum
transfer
h
challeng
expect
administr
antiserum
h
challeng
group
less
protect
group
even
condit
affect
mice
recov
clinic
sign
complet
disappear
day
postinfect
despit
inabl
mva
replic
mammalian
cell
vitro
vivo
even
immunocompromis
individu
gilbert
gomez
et
al
recombin
mva
vaccin
express
foreign
antigen
host
cell
upon
inocul
induc
immun
respons
specif
foreign
antigen
mva
vector
vaccin
viral
infect
proven
effect
wide
rang
viral
diseas
gilbert
chikungunya
garciaarriaza
et
al
sever
acut
respiratori
syndrom
chen
et
al
humor
cellular
immun
respons
elicit
foreign
mvaencod
antigen
higher
trigger
vaccinia
western
revers
strain
part
due
higher
level
express
foreign
antigen
mva
ramirez
et
al
moreov
mva
abl
elicit
strong
specif
respons
condit
preexist
immun
vector
ramirez
et
al
seen
previou
studi
use
mva
prime
boost
immunis
use
mva
base
vaccin
heterolog
primeboost
vaccin
regim
often
pursu
diseas
cellmedi
immun
definit
play
import
role
protect
case
plasmodium
falciparum
ogwang
et
al
hiv
gomez
et
al
cosma
et
al
influenza
berthoud
et
al
howev
mva
base
vaccin
also
abl
elicit
strong
antibodi
respons
draper
et
al
mva
use
develop
promis
antibodyinduc
vaccin
viral
surfac
protein
haemagglutinin
ha
influenza
viru
kreijtz
et
al
spike
glycoprotein
sar
chen
et
al
vaccin
studi
btv
mva
effect
vaccin
induc
robust
vnab
respons
express
protein
calvopinilla
et
al
jabbar
et
al
similarli
mva
express
shown
elicit
high
level
neutral
antibodi
castilloolivar
et
al
chiam
et
al
previou
passiv
immunis
studi
show
vaccin
induc
highli
protect
humor
immun
respons
ahsv
studi
ahsvspecif
interferonc
secret
cell
also
induc
vaccin
role
protect
could
evalu
time
previous
pretoriu
et
al
demonstr
increas
viru
specif
tcell
hors
respons
vaccin
live
attenu
ahsv
vaccin
studi
mice
use
recombin
mva
express
administ
combin
also
show
specif
tcell
respons
reduct
viraemia
follow
heterolog
challeng
de
la
poza
et
al
addit
recombin
canarypox
express
abl
induc
tcell
respons
alongsid
vnab
suggest
cellmedi
immun
could
play
signific
role
overal
level
protect
ahsv
el
garch
et
al
howev
clear
demonstr
protect
effect
effector
mechan
immun
adopt
transfer
tcell
yet
report
present
studi
adopt
transfer
splenocyt
vaccin
mice
significantli
reduc
clinic
score
ahsv
challeng
recipi
mice
result
surviv
although
chang
surviv
rate
reduct
viraemia
consid
mathemat
signific
suggest
role
cellmedi
immun
respons
less
import
antibodi
respons
protect
gener
vaccin
addit
argu
margin
protect
ahsv
shown
recipi
splenocyt
could
due
b
cell
contain
transfer
cell
addit
adopt
transfer
experi
use
cellsort
lymphocyt
donor
challeng
could
help
elucid
precis
contribut
cellmedi
immun
follow
vaccin
studi
relat
orbiviru
btv
adopt
transfer
cytotox
cell
btv
infect
sheep
partial
protect
recipi
sheep
infect
either
homolog
heterolog
btv
serotyp
jeggo
et
al
contrast
passiv
transfer
antibodi
infect
anim
perform
protect
complet
virul
viru
jeggo
et
al
case
ahsv
humor
natur
protect
viru
demonstr
passiv
transfer
monoclon
neutralis
antibodi
protein
neonat
mous
model
burrag
et
al
passiv
transfer
neutralis
antibodi
also
describ
ahsv
vaccin
mare
foal
via
colostrum
blackburn
swanepoel
crafford
et
al
present
studi
consist
previou
observ
highli
protect
effect
antiserum
deriv
vaccin
mice
also
demonstr
even
transfer
h
postinfect
antiserum
dose
increas
group
protect
effect
close
shown
activ
immun
vaccin
mice
limit
clinic
sign
still
evid
mice
infect
h
transfer
eventu
disappear
anim
recov
complet
group
suggest
passiv
immunis
antiserum
could
use
therapeut
applic
particular
emerg
treatment
ah
hors
initi
stage
outbreak
contain
measur
widespread
vaccin
campaign
initi
previou
studi
shown
vaccin
induc
high
vnab
respons
mice
hors
highli
protect
ahsv
experiment
system
conclud
protect
mainli
associ
antibodi
sinc
passiv
transfer
immun
serum
vaccin
mice
suffici
provid
clinic
protect
